{
    "nct_id": "NCT06344416",
    "official_title": "Study of Ribociclib (Ribo) Treatment Adherence Clinical Study Protocol",
    "inclusion_criteria": "Male or female, at least 18 years of age. Diagnosis of HR+ HER2- metastatic breast cancer with ribociclib treatment that begun within last 60 days.\n\nSite has ability to dispense ribociclib in long term. Participant is able to read, understand and sign the IRB research consent for use of their data for research purposes.\n\nParticipant is able and willing to complete Patient Reported Outcome (PRO) questionnaires during the study.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "â€¢ Participant has been routinely taking ribociclib for the past 60 days (without ReX platform).\n\nParticipants prescribed ribociclib for off-label indications. Participants who failed to pass the learning module during the ReX training process.\n\nParticipants who are at the end stage of their terminal illness with an anticipated life expectancy of 6 months or less.\n\nParticipants who have a significant physical disability (including poor fine motor skills, impaired visual or auditory faculties, mental disorders, or another impairment), affecting ability to provide IRB research consent or use the ReX dispensing unit effectively.\n\nParticipant is unsuited for participation in the study based on PI discretion\n\n-",
    "miscellaneous_criteria": ""
}